242 related articles for article (PubMed ID: 27598824)
41. New approaches to tackle cytopenic myelofibrosis.
Reynolds SB; Pettit K
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):235-244. PubMed ID: 36485113
[TBL] [Abstract][Full Text] [Related]
42. Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines.
Yang EG; Mustafa N; Tan EC; Poulsen A; Ramanujulu PM; Chng WJ; Yen JJ; Dymock BW
J Med Chem; 2016 Sep; 59(18):8233-62. PubMed ID: 27541357
[TBL] [Abstract][Full Text] [Related]
43. Investigational Janus kinase inhibitors.
Tam CS; Verstovsek S
Expert Opin Investig Drugs; 2013 Jun; 22(6):687-99. PubMed ID: 23432430
[TBL] [Abstract][Full Text] [Related]
44. What is next beyond janus kinase 2 inhibitors for primary myelofibrosis?
Santos FP; Verstovsek S
Curr Opin Hematol; 2013 Mar; 20(2):123-9. PubMed ID: 23385614
[TBL] [Abstract][Full Text] [Related]
45. Momelotinib expands the therapeutic armamentarium for myelofibrosis: Impact on hierarchy of treatment choices.
Tefferi A; Pardanani A; Gangat N
Am J Hematol; 2024 Feb; 99(2):300-308. PubMed ID: 38164985
[TBL] [Abstract][Full Text] [Related]
46. A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis.
Verstovsek S; Talpaz M; Ritchie E; Wadleigh M; Odenike O; Jamieson C; Stein B; Uno T; Mesa RA
Leukemia; 2017 Feb; 31(2):393-402. PubMed ID: 27479177
[TBL] [Abstract][Full Text] [Related]
47. Cytopenic myelofibrosis: prevalence, relevance, and treatment.
Vachhani P; Verstovsek S; Bose P
Expert Opin Pharmacother; 2023 Jun; 24(8):901-912. PubMed ID: 37070147
[TBL] [Abstract][Full Text] [Related]
48. Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis.
Pardanani A; Gotlib J; Roberts AW; Wadleigh M; Sirhan S; Kawashima J; Maltzman JA; Shao L; Gupta V; Tefferi A
Leukemia; 2018 Apr; 32(4):1035-1038. PubMed ID: 29263442
[No Abstract] [Full Text] [Related]
49. Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012.
Reilly JT; McMullin MF; Beer PA; Butt N; Conneally E; Duncombe AS; Green AR; Mikhaeel G; Gilleece MH; Knapper S; Mead AJ; Mesa RA; Sekhar M; Harrison CN
Br J Haematol; 2014 Nov; 167(3):418-20. PubMed ID: 24961987
[No Abstract] [Full Text] [Related]
50. Managing patients with myelofibrosis and thrombocytopenia.
Yilmaz M; Verstovsek S
Expert Rev Hematol; 2022 Mar; 15(3):233-241. PubMed ID: 35316110
[TBL] [Abstract][Full Text] [Related]
51. Emerging drugs for the treatment of Myelofibrosis.
Shreenivas A; Mascarenhas J
Expert Opin Emerg Drugs; 2018 Mar; 23(1):37-49. PubMed ID: 29480036
[TBL] [Abstract][Full Text] [Related]
52. Long-term Effects of the Janus Kinase 1/2 Inhibitor Ruxolitinib on Pulmonary Hypertension and the Cardiac Function in a Patient with Myelofibrosis.
Miyawaki H; Kioka H; Sato K; Kurashige M; Ozawa T; Shibayama H; Hikoso S; Morii E; Yamauchi-Takihara K; Sakata Y
Intern Med; 2020 Jan; 59(2):229-233. PubMed ID: 31534088
[TBL] [Abstract][Full Text] [Related]
53. JAK inhibition in myelofibrosis: how to sequence treatment in this new era of multiple options.
Stein BL
Leuk Lymphoma; 2023 Feb; 64(2):292-299. PubMed ID: 36301740
[TBL] [Abstract][Full Text] [Related]
54. Pacritinib demonstrates spleen volume reduction in patients with myelofibrosis independent of JAK2V617F allele burden.
Tremblay D; Mesa R; Scott B; Buckley S; Roman-Torres K; Verstovsek S; Mascarenhas J
Blood Adv; 2020 Dec; 4(23):5929-5935. PubMed ID: 33275766
[TBL] [Abstract][Full Text] [Related]
55. Long-term treatment with pacritinib on a compassionate use basis in patients with advanced myelofibrosis.
Harrison C; Yacoub A; Scott B; Mead A; Gerds AT; Kiladjian JJ; Mesa R; Egyed M; Scheid C; Gutierrez VG; O'Sullivan J; Buckley S; Kanellopoulos K; Mascarenhas J
Haematologica; 2023 Jul; 108(7):1960-1964. PubMed ID: 36601980
[No Abstract] [Full Text] [Related]
56. Pacritinib protects dendritic cells more efficiently than ruxolitinib.
Heine A; Wolf AM; Schlaweck S; Daecke SN; Brossart P; Wolf D
Exp Hematol; 2021 Aug; 100():37-40. PubMed ID: 34182006
[TBL] [Abstract][Full Text] [Related]
57. Emerging drugs for the treatment of myelofibrosis: phase II & III clinical trials.
Tremblay D; Hoffman R
Expert Opin Emerg Drugs; 2021 Dec; 26(4):351-362. PubMed ID: 34875179
[TBL] [Abstract][Full Text] [Related]
58. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis.
Pardanani A; Laborde RR; Lasho TL; Finke C; Begna K; Al-Kali A; Hogan WJ; Litzow MR; Leontovich A; Kowalski M; Tefferi A
Leukemia; 2013 Jun; 27(6):1322-7. PubMed ID: 23459451
[TBL] [Abstract][Full Text] [Related]
59. Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis.
Oh ST; Mesa RA; Harrison CN; Bose P; Gerds AT; Gupta V; Scott BL; Kiladjian JJ; Lucchesi A; Kong T; Buckley SA; Tyavanagimatt S; Harder BG; Roman-Torres K; Smith J; Craig AR; Mascarenhas J; Verstovsek S
Blood Adv; 2023 Oct; 7(19):5835-5842. PubMed ID: 37552106
[TBL] [Abstract][Full Text] [Related]
60. Current Clinical Investigations in Myelofibrosis.
Venugopal S; Mascarenhas J
Hematol Oncol Clin North Am; 2021 Apr; 35(2):353-373. PubMed ID: 33641874
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
